Needham & Company LLC Reiterates Buy Rating for Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at Needham & Company LLC in a research note issued on Monday,Benzinga reports. They currently have a $10.00 target price on the stock. Needham & Company LLC's price objective would indicate a potential upside of 283.14% from the stock's previous close.

Separately, Truist Financial lowered their target price on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Autolus Therapeutics currently has a consensus rating of "Buy" and an average target price of $9.32.

Autolus Therapeutics Stock Performance

Shares of NASDAQ AUTL traded up $0.18 during mid-day trading on Monday, reaching $2.61. 1,351,326 shares of the company traded hands, compared to its average volume of 1,568,121. The stock has a market cap of $694.63 million, a PE ratio of -2.97 and a beta of 1.81. The company's fifty day moving average is $2.04 and its two-hundred day moving average is $1.89. Autolus Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The company had revenue of $8.98 million during the quarter, compared to analyst estimates of $1.59 million. Research analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in AUTL. Forefront Wealth Management Inc. bought a new position in Autolus Therapeutics in the second quarter valued at $61,000. Avanza Fonder AB boosted its position in Autolus Therapeutics by 151.6% during the second quarter. Avanza Fonder AB now owns 53,522 shares of the company's stock valued at $122,000 after buying an additional 32,246 shares during the period. Atle Fund Management AB boosted its position in Autolus Therapeutics by 130.5% during the second quarter. Atle Fund Management AB now owns 1,105,461 shares of the company's stock valued at $2,520,000 after buying an additional 625,817 shares during the period. Jane Street Group LLC boosted its holdings in shares of Autolus Therapeutics by 809.4% during the first quarter. Jane Street Group LLC now owns 102,493 shares of the company's stock worth $159,000 after purchasing an additional 91,222 shares during the period. Finally, Armistice Capital LLC boosted its holdings in shares of Autolus Therapeutics by 19.6% during the first quarter. Armistice Capital LLC now owns 11,000,000 shares of the company's stock worth $17,050,000 after purchasing an additional 1,800,000 shares during the period. Institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.